表觀遺傳學市場規模、佔有率和成長分析（按產品、技術、方法、應用、最終用途和地區）- 產業預測 2025-2032

表觀遺傳學市場規模預計在 2023 年達到 16 億美元，並從 2024 年的 18.4 億美元成長到 2032 年的 55.4 億美元，預測期內（2025-2032 年）的複合年成長率為 14.8%。

除了 DNA定序之外，市場還在很大程度上受到對基因調控理解的進步的推動，從而增強疾病研究並支持個人化醫療的進步。未來幾年，預計投資增加將進一步加速這一成長。然而，全球癌症疫情也帶來了挑戰，預計2023年將報告約2000萬新患者和1000萬癌症相關死亡病例，到2040年每年將新增3000萬例癌症病例。雖然目前的治療方法，包括酵素抑制劑和免疫療法，正在獲得關注，但表觀遺傳療法作為治療癌症和神經系統疾病的潛在策略在未來仍具有廣闊的前景。總體而言，表觀遺傳學的鞏固和癌症發病率的上升表明未來市場前景強勁。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

表觀遺傳學市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 套件和試劑
  • 抗體
  • ChIP定序套件
  • 全基因組擴增試劑套件
  • 亞硫酸鹽轉化試​​劑套件
  • RNA定序套件
  • 5-HMC 和 5-MC 分析套件和試劑
  • 組蛋白
  • 其他
• 裝置
• 酵素
  • DNA修飾酶
  • 蛋白質修飾酶
  • 其他酵素
• 服務

表觀遺傳學市場規模（依技術及複合年成長率） (2025-2032)

• 市場概況
• DNA甲基化
• 組蛋白甲基化
• 組蛋白乙醯化
• 大型非編碼RNA
• 微型RNA修飾
• 染色質結構

表觀遺傳學市場規模（依方法論和複合年成長率） (2025-2032)

• 市場概況
• NGS
• PCR 和 QPCR
• 質譜分析
• 超音波
• 其他技術

表觀遺傳學市場規模（按應用和複合年成長率） (2025-2032)

• 市場概況
• 腫瘤學
  • 固態腫瘤
  • 液體腫瘤
• 非腫瘤科 腫瘤科
  • 發炎性疾病
  • 代謝紊亂
  • 感染疾病
  • 心血管疾病
  • 其他

表觀遺傳學市場規模（依最終用途和複合年成長率） (2025-2032)

• 市場概況
• 學術研究
• 臨床研究
• 醫院和診所
• 製藥和生物技術公司
• 其他用戶

表觀遺傳學市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Thermo Fisher Scientific Inc.（United States）
• Illumina, Inc.（United States）
• Merck KGaA（Germany）
• QIAGEN NV（Netherlands）
• Pacific Biosciences of California, Inc.（United States）
• Bio-Rad Laboratories, Inc.（United States）
• PerkinElmer, Inc.（United States）
• 10x Genomics, Inc.（United States）
• Active Motif, Inc.（United States）
• Zymo Research Corporation（United States）
• New England Biolabs, Inc.（United States）
• Promega Corporation（United States）
• Novartis AG（Switzerland）
• Element Biosciences, Inc.（United States）
• Dovetail Genomics LLC（United States）
• Storm Therapeutics（United Kingdom）

結論和建議

Epigenetics Market size was valued at USD 1.6 billion in 2023 and is poised to grow from USD 1.84 billion in 2024 to USD 5.54 billion by 2032, growing at a CAGR of 14.8% during the forecast period (2025-2032).

The market is poised for significant growth driven by advancements in understanding gene regulation beyond DNA sequencing, which enhances disease research and supports the evolution of personalized medicine. Increased investments are anticipated to further amplify this growth in the coming years. However, the global cancer epidemic poses challenges, with approximately 20 million new cases and 10 million cancer-related deaths reported in 2023, and projections suggesting 30 million cases annually by 2040. Current treatments, including enzyme inhibitors and immunotherapy, are gaining traction, while the future of epigenetic therapy appears promising as a potential leading strategy for addressing cancer and neurological disorders. Overall, the integration of epigenetics and a growing cancer prevalence signal a robust market trajectory ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Epigenetics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Epigenetics Market Segments Analysis

Global Epigenetics Market is segmented by Product, Technology, Technique, Application, End-use and region. Based on Product, the market is segmented into Kits & Reagents, Instruments, Enzymes and Services. Based on Technology, the market is segmented into DNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification and Chromatin structures. Based on Technique, the market is segmented into NGS, PCR & QPCR, Mass Spectrometry, Sonication and Other Techniques. Based on Application, the market is segmented into Oncology and Non-oncology oncology. Based on End-use, the market is segmented into Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Other Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Epigenetics Market

A key factor propelling the epigenetics market is the increasing incidence of cancer and various chronic diseases, including cardiovascular conditions. The role of epigenetic modifications, such as DNA methylation and histone alterations, is crucial in the progression of these diseases. This scenario has led to substantial investments in financial and medical advancements, particularly as precision medicine gains traction. Epigenetic therapies are emerging as viable options for personalized treatments, thereby enhancing the demand for epigenetic products and services. As a result, the epigenetics market is experiencing significant growth driven by these evolving healthcare needs and innovations.

Restraints in the Epigenetics Market

While the potential of the epigenetics market is promising, significant obstacles exist that hinder its expansion. A primary challenge is the substantial expense associated with epigenetic research and the development of therapeutic interventions. Conducting epigenetic studies typically necessitates sophisticated technologies and equipment, including next-generation sequencing (NGS) and chromatin immunoprecipitation (ChIP), which can entail high acquisition and operational costs. Consequently, these financial barriers restrict the availability of epigenetic tools and therapies, particularly in developing regions where healthcare budgets are limited, ultimately impeding broader market growth in the field of epigenetics.

Market Trends of the Epigenetics Market

The epigenetics market is witnessing a significant trend driven by advances in epigenetic editing technologies, particularly the emergence of precise CRISPR/Cas9-based tools. These innovations enable researchers to modify epigenetic marks with high specificity, facilitating detailed studies on gene regulation without changing the DNA sequence. As the adoption of these technologies increases, they are poised to transform epigenetic research and unlock new therapeutic avenues, particularly in oncology, neurobiology, and autoimmune conditions. This trend is expected to boost investment in research and development, leading to breakthroughs in understanding complex diseases and enhancing treatment strategies in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Epigenetics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Kits & Reagents
  • Antibodies
  • ChIP sequencing kit
  • Whole Genomic Amplification kit
  • Bisulfite Conversion kit
  • RNA sequencing kit
  • 5-HMC & 5-MC Analysis Kits& Reagents
  • Histones
  • Others
• Instruments
• Enzymes
  • Dna-Modifying Enzymes
  • Protein-Modifying Enzymes
  • Other Enzymes
• Services

Global Epigenetics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large non-coding RNA
• MicroRNA modification
• Chromatin structures

Global Epigenetics Market Size by Technique & CAGR (2025-2032)

• Market Overview
• NGS
• PCR & QPCR
• Mass Spectrometry
• Sonication
• Other Techniques

Global Epigenetics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
  • Solid tumors
  • Liquid tumors
• Non-oncology oncology
  • Inflammatory diseases
  • Metabolic diseases
  • Infectious diseases
  • Cardiovascular diseases
  • Others

Global Epigenetics Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users

Global Epigenetics Market Size & CAGR (2025-2032)

• North America (Product, Technology, Technique, Application, End-use)
  • US
  • Canada
• Europe (Product, Technology, Technique, Application, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Technique, Application, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Technique, Application, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Technique, Application, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 10x Genomics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Active Motif, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymo Research Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Element Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dovetail Genomics LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Storm Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations